Short answer
Beam Therapeutics Inc. (BEAM) filed its Q3 2025 10-Q quarterly report on Nov 4, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $10M (down 32.0% year over year) with net income of −$113M.
Q3 2025 key financials · XBRL
- Revenue
- $10M
- −32.0% YoY · +14.6% QoQ
- Net income
- −$113M
- −16.6% YoY · −10.2% QoQ
- Operating margin
- -1307.6%
- EPS (diluted)
- −$1.09
- +7.6% YoY · −10.1% QoQ
Source: XBRL data from the Beam Therapeutics Inc. (BEAM) Q3 2025 10-Q on SEC EDGAR. USD.
Beam Therapeutics Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New regulatory risk: FDA orphan drug and regenerative medicine advanced therapy designations granted for BEAM-302 in 2025, triggering expanded clinical trial and regulatory requirements
- Updated clinical risk: BEACON trial interim data on BEAM-101 showed sustained mean total Hb increase to 15.6 g/dL at month six, with no Grade 3+ adverse events reported
- Legal/licensing risk: $200M upfront and up to $350M in milestone payments under Eli Lilly agreement for Verve programs, with $25M received through Q3 2025
- Operational risk: Early-stage Phase 1/2 trials underway for BEAM-301 and BEAM-302 with ongoing dose escalation and safety monitoring critical for near-term pipeline progress
- Financial risk: Collaboration revenue included a $3.8M Apellis cash opt-in fee in Q3 2025, reflecting dependency on partner licensing for near-term cash inflows
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Beam Therapeutics Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.